S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

(I.TO) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume7,625 shs
Average Volume16,872 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Industry, Sector and Symbol

Industry N/A
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A


Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive I News and Ratings via Email

Sign-up to receive the latest news and ratings for I and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

(I.TO) (TSE:I) Frequently Asked Questions

What stocks does MarketBeat like better than (I.TO)?

Wall Street analysts have given (I.TO) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (I.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are (I.TO)'s key executives?

(I.TO)'s management team includes the following people:
  • Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
  • Amina Odidi Ph.D., President, Chief Operating Officer, Director
  • Andrew Patient, Chief Financial Officer
  • John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
  • Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
  • Kenneth Keirstead, Independent Director
  • Bahadur Madhani, Independent Director
  • Eldon R. Smith M.D., Independent Director (Age 75)

What other stocks do shareholders of (I.TO) own?

What is (I.TO)'s stock symbol?

(I.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "I."

How do I buy shares of (I.TO)?

Shares of I and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does (I.TO) make?

(I.TO) has a market capitalization of C$0.00.

Where are (I.TO)'s headquarters?

(I.TO) is headquartered at 30 Worcester Rd, ETOBICOKE, ON M9W 5X2, Canada.

How can I contact (I.TO)?

(I.TO)'s mailing address is 30 Worcester Rd, ETOBICOKE, ON M9W 5X2, Canada. The company can be reached via phone at +1-416-7983001.

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.